Literature DB >> 6028026

Aminoaciduria resulting from cycloleucine administration in man.

R R Brown.   

Abstract

Cycloleucine (1-aminocyclopentanecarboxylic acid) administration in cancer patients resulted in a reversible marked aminoaciduria consisting predominantly of cystine, ornithine, lysine, and arginine, with only minor elevations of other amino acids. Plasma levels of amino acids were essentially unchanged except for slight decreases in ornithine and lysine. This aminoaciduria is most likely due to a blockage by the drug of the renal tubular reabsorption of cystine, ornithine, lysine, and arginine, resulting in an aminoaciduria of the type seen in cystinuria.

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 6028026     DOI: 10.1126/science.157.3787.432

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  5 in total

1.  Cycloleucine (1-amino-cyclopentane carboxylic acid): tubular reabsorption and inhibitory effect on amino acid transport in the rat kidney. (Microperfusion experiments).

Authors:  S Silbernagl
Journal:  Pflugers Arch       Date:  1975       Impact factor: 3.657

2.  Immunopharmacologic activity of 1-aminocyclopentane-1-carboxylic acid.

Authors:  M E Rosenthale; M I Gluckman
Journal:  Experientia       Date:  1968-12-15

3.  Transport of L-cystine in isolated perfused proximal straight tubules.

Authors:  J A Schafer; M L Watkins
Journal:  Pflugers Arch       Date:  1984-06       Impact factor: 3.657

4.  Mutual inhibition of L-cystine/L-cysteine and other neutral amino acids during tubular reabsorption. A microperfusion study in rat kidney.

Authors:  H Völkl; S Silbernagl
Journal:  Pflugers Arch       Date:  1982-11-11       Impact factor: 3.657

5.  Evidence that cycloleucine affects the high-affinity systems of amino acid uptake in cultured human fibroblasts.

Authors:  M Feneant; N Moatti; J Maccario; M Gautier; S Guerroui; A Lemonnier
Journal:  Biochem J       Date:  1984-11-15       Impact factor: 3.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.